Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The successful incorporation of tyrosine kinase inhibitors (TKIs) to chemotherapy regimens in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) has significantly improved the outcome of these patients. This advancement has also generated several new areas of investigation such as identifying the role of reduced or chemotherapy-free induction therapy, the best TKI option, the benefit of allogeneic hematopoietic stem cell transplant (HSCT) in first remission, and the effect of prophylactic TKI post-HSCT in patients with Ph-positive ALL. Novel treatment modalities such as bispecific T-cell engagers (e.g., blinatumomab), drug conjugate monoclonal antibodies (e.g., inotuzumab ozogamicin), more potent TKIs, and chimeric antigen receptor T-cell therapies are being investigated. In this chapter, we will provide an overview of the current and future treatment paradigms for Ph-positive ALL.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Pages219-233
Number of pages15
DOIs
StatePublished - 2021

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this